Rapid Response Vaccine Platform
20Med Nanoparticles have the potential to become the backbone of future RNA and DNA based vaccines. Due to its product characteristics that are very favorable for scale-up of production, ease of formulation, and lyophilization capability resulting in a thermostable final vaccine, 20Med Nanoparticle technology can revolutionize the development of mRNA vaccines.
More information on our Rapid Response Vaccine Platform using 20Med Nanoparticles:
20Med Therapeutics' non-viral delivery technology for development of RNA/DNA based vaccines and therapeutics
Resulting from 15 years of research 20Med Nanoparticles have been specifically designed to address all aspects of intracellular drug and gene delivery. 20Med Nanoparticles are particularly useful for delivery of oligonucleotide based vaccines and therapeutics, providing protection of fragile payloads. Efficient cell entry and endosomal escape followed by rapid bioresponsive release from the nanoparticles deliver RNA and DNA-based therapeutics to the desired intracellular location.
For more information on how our Nanoparticle Technology Platform works: